|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Bryant J et al. Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr 2001;(30):56-61. Abstract
Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-717. Abstract
Fisher B et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93(9):684-90. Abstract
National Cancer Institute (NCI). Clinical alert: Adjuvant therapy of breast cancer — Tamoxifen update. 1995. Available at: www.nlm.nih.gov/databases/alerts/tamoxifen.html.
Peto R et al. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women — Preliminary results. Presentation. San Antonio Breast Cancer Symposium 2007a;Abstract 48.
Peto R et al. The worldwide overview: Updated (2005-6) meta-analyses of trial results. Presentation. San Antonio Breast Cancer Symposium 2007b. No abstract available
 |
 |
EDITOR'S NOTE
San Antonio adventure, 2007
Neil Love, MD
- Select publications
INTERVIEWS
Stephen E Jones, MD
- Select publications
Sir Richard Peto, FRS
- Select publications
Kathy S Albain, MD
- Select publications
Roundtable Discussion
- Select publications
Joyce O’Shaughnessy, MD
- Select publications
Nancy U Lin, MD
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
